Literature DB >> 305890

Active suppression of in vitro reactivity of spleen cells after BCG treatment.

S Orbach-Arbouys, M F Poupon.   

Abstract

It was found that spleen cells from mice injected i.v. with large doses of BCG respond to PHA stimulation less intensely than do normal spleen cells. We were able to show that nylon wool column purified BCG treated T cells also had a low PHA reactivity. Unfractionated spleen cells, adherent cells or T-enriched populations from BCG treated mice, when added to normal T cells lowered their PHA reactivity. When the same BCG treated cell populations were added to tumor cells in vitro, they inhibited their growth.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305890      PMCID: PMC1457593     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

1.  [Spleen reactivity after BCG treatement: test and strain dependency of the response].

Authors:  I Florentin; S Orbach-Arbouys
Journal:  Ann Immunol (Paris)       Date:  1977 Jan-Mar

2.  The influence upon mitogenic and cellular immunologic reactive systems in vitro by poly(I:C) and BCG murine interferons induced in vivo.

Authors:  B A Clinton; T J Magoc; R L Aspinall; N P Rapoza
Journal:  Cell Immunol       Date:  1976-11       Impact factor: 4.868

3.  Cytostatic effect of spleen cells of tumor-bearing mice on syngenetic tumor cells.

Authors:  G Lespinats; M F Poupon
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

4.  Macrophage regulation of mitogen-induced blastogenesis. I. Demonstration of inhibitory cells in the spleens and peritoneal exudates of mice.

Authors:  L G Baird; A M Kaplan
Journal:  Cell Immunol       Date:  1977-01       Impact factor: 4.868

5.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

6.  Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells.

Authors:  T E Miller; G B Mackaness; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

7.  On the mode of action of BCG.

Authors:  M S Mitchell; D Kirkpatrick; M B Mokyr; I Gery
Journal:  Nat New Biol       Date:  1973-06-13

8.  Active immunotherapy for acute lymphoblastic leukaemia.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F De Vassal
Journal:  Lancet       Date:  1969-04-05       Impact factor: 79.321

9.  Specific and nonspecific antitumor immunity. II. Macrophage-mediated nonspecific effector activity induced by BCG and similar agents.

Authors:  R N Germain; R M Williams; B Benacerraf
Journal:  J Natl Cancer Inst       Date:  1975-03       Impact factor: 13.506

10.  The modifying effect of BCG on the immunological induction of T cells.

Authors:  G B Mackaness; P H Lagrange; T Ishibashi
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  18 in total

1.  Suppressor T-cells in BCG-infected mice.

Authors:  F M Collins; S R Watson
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

2.  Induction by an immunogenic immunomodulating agent of nonspecific T cell suppression of lymphocyte responsiveness in MLR but not of antibody production.

Authors:  C Reuben; D Halperin; S Ben-Efraim; D W Weiss
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Suppressed or enhanced antibody responses in vitro after BCG treatment of mice: importance of BCG viability.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

4.  The responsiveness of efferent lymph cells to phytohaemagglutinin during the response of the popliteal node to dinitrophenylated bovine serum albumin.

Authors:  L S English
Journal:  Immunology       Date:  1979-10       Impact factor: 7.397

5.  The immunologic and immunotherapeutic sequelae of intraperitoneal BCG. II: Serial changes in spleen weight, morphology, cell populations and in vitro mitogen responses.

Authors:  W R Roche; H McLaughlin
Journal:  Ir J Med Sci       Date:  1983-08       Impact factor: 1.568

6.  Chemotherapy, a double agent in respect of immune functions.

Authors:  G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Immune response to atypical mycobacteria: immunocompetence of heavily infected mice measured in vivo fails to substantiate immunosuppression data obtained in vitro.

Authors:  I M Orme; F M Collins
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

8.  Suppression of T-cell responses to histocompatibility antigens by BCG pre-treatment.

Authors:  S Orbach-Arbouys; M Castes
Journal:  Immunology       Date:  1980-02       Impact factor: 7.397

9.  Active suppression masks an underlying enhancement of antibody production in vitro by spleen cells from BCG-infected mice.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

10.  Comparison between immunopotency tests and specific active or passive acquired resistance against Mycobacterium tuberculosis in mice induced with three different preparations of BCG pasteur vaccine.

Authors:  M Brandely; B Hurtrel; P H Lagrange
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.